(Q39421539)

11 September 2017

title

Pharmacologic inhibition of mTOR antagonizes the cytotoxic activity of pemetrexed in non-small cell lung cancer (English)

1 reference

11 September 2017

0 references

Boyka Markova

1 reference

11 September 2017

Patricia S Hähnel

1 reference

11 September 2017

Stefan Kasper

1 reference

11 September 2017

Stephan Herbertz

1 reference

11 September 2017

Martin Schuler

1 reference

11 September 2017

Frank Breitenbuecher

1 reference

11 September 2017

publication date

28 December 2011

1 reference

Journal of Cancer Research and Clinical Oncology

11 September 2017

published in

1 reference

11 September 2017

volume

138

1 reference

11 September 2017

1 reference

11 September 2017

page(s)

545-554

1 reference

Emerging targeted therapies for breast cancer

11 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00432-011-1123-9

BCR-ABL tyrosine kinase inhibitors in the treatment of Philadelphia chromosome positive chronic myeloid leukemia: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-011-1123-9

The selectivity of protein kinase inhibitors: a further update

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-011-1123-9

Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-011-1123-9

Clinical efficacy and predictive molecular markers of neoadjuvant gemcitabine and pemetrexed in resectable non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-011-1123-9

Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-011-1123-9

Specificity and mechanism of action of some commonly used protein kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-011-1123-9

Clinical management of gastrointestinal stromal tumors: before and after STI-571.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-011-1123-9

Inhibition of the Bcr-Abl tyrosine kinase as a therapeutic strategy for CML.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-011-1123-9

ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-011-1123-9

Synergistic antitumor activity of TRAIL combined with chemotherapeutic agents in A549 cell lines in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-011-1123-9

Enhancement of Apo2L/TRAIL (tumor necrosis factor-related apoptosis-inducing ligand)-induced apoptosis in non-small cell lung cancer cell lines by chemotherapeutic agents without correlation to the expression level of cellular protease caspase-8 inh

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-011-1123-9

Mammalian target of rapamycin as a therapeutic target in leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-011-1123-9

Targeting AKT signaling sensitizes cancer to cellular immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-011-1123-9

Role of mTOR in anticancer drug resistance: perspectives for improved drug treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-011-1123-9

mTOR signaling at a glance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-011-1123-9

Targeting the PI3K/Akt/mTOR pathway: effective combinations and clinical considerations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-011-1123-9

Significance of thymidylate synthase for resistance to pemetrexed in lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-011-1123-9

Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-011-1123-9

Thymidylate synthase but not excision repair cross-complementation group 1 tumor expression predicts outcome in patients with malignant pleural mesothelioma treated with pemetrexed-based chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-011-1123-9

The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-011-1123-9

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-011-1123-9

Growing roles for the mTOR pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-011-1123-9

Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-011-1123-9

Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-011-1123-9

SDZ RAD, a new rapamycin derivative: pharmacological properties in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-011-1123-9

Induction of resistance to the multitargeted antifolate Pemetrexed (ALIMTA) in WiDr human colon cancer cells is associated with thymidylate synthase overexpression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-011-1123-9

Inhibition of PI3K-AKT-mTOR signaling sensitizes melanoma cells to cisplatin and temozolomide

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-011-1123-9

mTOR-targeted therapy of cancer with rapamycin derivatives

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-011-1123-9

TOR signaling in growth and metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-011-1123-9

First-line use of EGFR tyrosine kinase inhibitors in patients with NSCLC containing EGFR mutations.

21 January 2018

1 reference

12 December 2020

Mammalian target of rapamycin: a central node of complex signaling cascades

1 reference

12 December 2020

Squamous cell carcinoma of the lung compared with other histotypes shows higher messenger RNA and protein levels for thymidylate synthase

1 reference

12 December 2020

In vitro chemosensitivity of freshly explanted tumor cells to pemetrexed is correlated with target gene expression

1 reference

12 December 2020

Enhancing the efficacy of hormonal agents with selected targeted agents

1 reference

12 December 2020

Everolimus: the first approved product for patients with advanced renal cell cancer after sunitinib and/or sorafenib

1 reference

12 December 2020

LY231514, a pyrrolo[2,3-d]pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes

1 reference

12 December 2020

Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins

1 reference

12 December 2020

10.1007/S00432-011-1123-9

Identifiers

DOI

1 reference

11 September 2017

1 reference